Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Data regarding efficacy and toxicity of chimeric antigen receptor T (CAR-T) cell therapy in the elderly, geriatric population are insufficient. In 2019, tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed/refractory diffuse large B-cell lymphoma. From May 2019 onward...

Descripción completa

Detalles Bibliográficos
Autores principales: Ram, Ron, Grisariu, Sigal, Shargian-Alon, Liat, Amit, Odelia, Bar-On, Yaeli, Stepensky, Polina, Yeshurun, Moshe, Avni, Batia, Hagin, David, Perry, Chava, Gurion, Ronit, Sarid, Nadav, Herishanu, Yair, Gold, Ronit, Glait-Santar, Chen, Kay, Sigi, Avivi, Irit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052918/
https://www.ncbi.nlm.nih.gov/pubmed/34233446
http://dx.doi.org/10.3324/haematol.2021.278288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052918/
https://www.ncbi.nlm.nih.gov/pubmed/34233446
http://dx.doi.org/10.3324/haematol.2021.278288

Ejemplares similares